Until mid-October, cancer immunotherapy play Medigene AG was a pure drug developer. With a potential US$1bn TCR-contract manufacturing deal with Bluebird Bio, it widened its business focus. Now, the company presented a process that delivers neospecific anti-tumour TCRs.

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.